CAS: 84-96-8; N,N,2-Trimethyl-3-(10H-Phenothiazin-10-yl)Propan-1-Amine

上下游产品

10-allylphenothiazine carbon monoxide dimethyl amine formaldehyd10-3-(dimethylamino-2-methylpropyl)phenothiazine cation formaldehyd

📜吩噻嗪置于chloro(1,5-Cyclooctadiene)Rhodium(I) Dimer,氢气体系中,120.0 °C,11.0 Mpa 条件下,反应 48.0H,反应生成 异丁嗪
参考文献:通过铑催化杂环烯丙基胺的羰基化氢氨基甲基化一锅合成药理活性二胺
标题:通过铑催化杂环烯丙基胺的羰基化氢氨基甲基化一锅合成药理活性二胺
摘要:吩噻嗪,亚氨基二苄基,咔唑和吡唑的药理活性衍生物是通过使相应的n-烯丙基或n-甲基烯丙基化合物,伯或仲胺,一氧化碳和氢在[rh(cod)cl通过一锅加氢甲酰化-胺缩合-还原顺序得到作为催化剂的] 2.图选项
DOI:10.1016/s0040-4020(99)00536-0

专利信息

专利号:US-6264962-B1
优先权日:1997-12-19
标 题:Use of cinnamic acid or of at least one of its derivatives in a cosmetic composition
发明人：BRETON LIONEL; GIRERD FLORENCE; RENAULT BEATRICE
权利人:OREAL
摘要:The invention relates to the use of cinnamic acid, or of at least one of its derivatives, in a cosmetic composition as an agent for promoting the synthesis of the skin's total lipids. n The invention also relates to a cosmetic composition comprising an effective amount of cinnamic acid or of at least one of its derivatives.

专利号:WO-2025069039-A1
优先权日:2023-09-28
标题:An in situ process for the preparation of primary amine compounds
发明人：SAMANT RAJARAM; TONGRA MANOJ
权利人:SAMANT RAJARAM; TONGRA MANOJ
摘要:An in situ process for the preparation of primary amine compounds The invention disclosed herein relates to an in situ process for the preparation of primary amine compounds. Particularly, it relates to the preparation of primary amine compounds having general Formula (I). Formula (I) wherein n is 1 to 9 and X is -S, -N- or -O. More particularly, the present invention relates to the preparation of primary amine compounds with high yield and purity which is further used as potent intermediate in the synthesis of therapeutically active isothiocyanates (ITCs).

专利号:EP-1331924-B1
优先权日:2000-10-26
标题 :Use of beta-carotene and lycopene for treating ageing symptoms via the inhibition of the expression of the metalloproteinase of type 1 of the extracellular matrix
发明人：BRETON LIONEL; BAUR MARKUS
权利人:OREAL; NESTEC SA
摘要:Intimate admixtures of at least one carotenoid having provitamin A activity and at least one carotenoid devoid of provitamin A activity are well suited for treating the undesirable cutaneous signs of skin aging, in particular the determination of the skin and/or of the mucous membranes by inhibiting the activity and/or the expression of collagenases and by increasing the synthesis of collagen.

专利号:US-7919505-B2
优先权日:2006-07-11
标题 :Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
发明人：TING PAULINE C; LEE JOE F; FENG KUNG-I; REEDER MICHAEL R; TRZASKA SCOTT T; ZHU MAN; MAO CHEN; FILIPOV DIMITAR L; ZARKADAS DIMITRIOS N
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the formula n nTo methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

专利号:US-6660283-B2
优先权日:1997-12-19
标 题 :Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition
发明人：BRETON LIONEL; GIRERD FLORENCE; RENAULT BEATRICE
权利人:OREAL
摘要:The invention relates to the use of cinnamic acid, or of at least one of its derivatives, in a cosmetic composition as an agent for promoting the synthesis of the skin's total lipids.The invention also relates to a cosmetic composition comprising an effective amount of cinnamic acid or of at least one of its derivatives.

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.